CN111991386A - 降低受试者的心血管事件的风险的方法 - Google Patents

降低受试者的心血管事件的风险的方法 Download PDF

Info

Publication number
CN111991386A
CN111991386A CN202011011284.6A CN202011011284A CN111991386A CN 111991386 A CN111991386 A CN 111991386A CN 202011011284 A CN202011011284 A CN 202011011284A CN 111991386 A CN111991386 A CN 111991386A
Authority
CN
China
Prior art keywords
subject
risk
cardiovascular
epa
flutter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011011284.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·索尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Pharmaceuticals Ireland Ltd
Original Assignee
Amarin Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69884391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111991386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Pharmaceuticals Ireland Ltd filed Critical Amarin Pharmaceuticals Ireland Ltd
Publication of CN111991386A publication Critical patent/CN111991386A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
CN202011011284.6A 2018-09-24 2019-04-22 降低受试者的心血管事件的风险的方法 Pending CN111991386A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862735680P 2018-09-24 2018-09-24
US201862735670P 2018-09-24 2018-09-24
US62/735,680 2018-09-24
US62/735,670 2018-09-24
US201862758387P 2018-11-09 2018-11-09
US62/758,357 2018-11-09
US201962813888P 2019-03-05 2019-03-05
US62/813,888 2019-03-05
US201962818514P 2019-03-14 2019-03-14
US62/818,514 2019-03-14
CN201980016642.1A CN112218630A (zh) 2018-09-24 2019-04-22 降低受试者的心血管事件的风险的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980016642.1A Division CN112218630A (zh) 2018-09-24 2019-04-22 降低受试者的心血管事件的风险的方法

Publications (1)

Publication Number Publication Date
CN111991386A true CN111991386A (zh) 2020-11-27

Family

ID=69884391

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011011284.6A Pending CN111991386A (zh) 2018-09-24 2019-04-22 降低受试者的心血管事件的风险的方法
CN201980016642.1A Pending CN112218630A (zh) 2018-09-24 2019-04-22 降低受试者的心血管事件的风险的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980016642.1A Pending CN112218630A (zh) 2018-09-24 2019-04-22 降低受试者的心血管事件的风险的方法

Country Status (27)

Country Link
US (10) US10668042B2 (enExample)
EP (4) EP3750535A1 (enExample)
JP (3) JP7020756B2 (enExample)
KR (4) KR20230038594A (enExample)
CN (2) CN111991386A (enExample)
AU (6) AU2019349563B2 (enExample)
BR (1) BR112021005580A2 (enExample)
CL (3) CL2021000645A1 (enExample)
DK (1) DK4056176T3 (enExample)
ES (1) ES2983568T3 (enExample)
FI (1) FI4056176T3 (enExample)
HR (1) HRP20240898T1 (enExample)
HU (1) HUE067138T2 (enExample)
IL (1) IL279494A (enExample)
LT (1) LT4056176T (enExample)
MA (3) MA51766A (enExample)
MX (2) MX2021002553A (enExample)
NI (1) NI202100014A (enExample)
PL (1) PL4056176T3 (enExample)
PT (1) PT4056176T (enExample)
RS (1) RS65750B1 (enExample)
SG (1) SG11202102872QA (enExample)
SI (1) SI4056176T1 (enExample)
SM (1) SMT202400320T1 (enExample)
TN (1) TN2021000013A1 (enExample)
WO (1) WO2020068163A1 (enExample)
ZA (2) ZA202007993B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
LT2424356T (lt) 2009-04-29 2017-11-27 Amarin Pharmaceuticals Ireland Limited Stabili farmacinė kompozicija ir jos panaudojimo būdai
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
CN104582698A (zh) 2012-06-29 2015-04-29 阿玛林制药爱尔兰有限公司 在接受抑制素治疗的受试者中降低心血管事件风险的方法
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20230038594A (ko) * 2018-09-24 2023-03-20 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2024224234A1 (en) * 2023-04-23 2024-10-31 Vishal Kumar Pharmaceutical composition in powder form in sachets and tablet of 90 mg ticagrelor + 20 mg rosuvastatin
WO2025100587A1 (ko) * 2023-11-08 2025-05-15 경상국립대학교병원 경피적 관상동맥중재술 이후 예후 예측에 대한 정보 제공 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582698A (zh) * 2012-06-29 2015-04-29 阿玛林制药爱尔兰有限公司 在接受抑制素治疗的受试者中降低心血管事件风险的方法

Family Cites Families (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
AU527784B2 (en) 1978-05-26 1983-03-24 Bang, Hans Olaf Dr. Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS6135356A (ja) 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd 血液脂質脂肪酸の分析方法
EP0347509A1 (en) 1988-06-21 1989-12-27 Century Laboratories Inc. A process of extraction and purification of polyunsaturated fatty acids from natural sources
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
AU602376B2 (en) 1986-12-26 1990-10-11 Sagami Chemical Research Center Process for production of eicosapentaenoic acid
JPS63185390A (ja) 1987-01-27 1988-07-30 Suntory Ltd 藻類によるエイコサペンタエン酸の製造方法
US5252333A (en) 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5262168A (en) 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IE63225B1 (en) 1988-09-13 1995-04-05 Efamol Holdings Use of fatty acids in the treatment of myalgic encephalomyelitis
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
DK95490D0 (da) 1990-04-18 1990-04-18 Novo Nordisk As Fremgangsmaade til fremstilling af triglycerid og triglyceridsammensaetning
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (ja) 1990-11-16 2000-10-30 持田製薬株式会社 リポプロテイン（ａ）低下剤
US5262437A (en) 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5215630A (en) 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
AU2384292A (en) 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (de) 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
JPH0692847A (ja) 1992-09-11 1994-04-05 Mochida Pharmaceut Co Ltd 骨粗鬆症治療剤
WO1994010125A1 (en) 1992-10-27 1994-05-11 Sandoz Ltd. Glycerin derivatives and uses thereof
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9318611D0 (en) 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JP3325995B2 (ja) 1994-02-28 2002-09-17 ミサワホーム株式会社 パネル接合構造
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9404483D0 (en) 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JP3368100B2 (ja) 1994-06-02 2003-01-20 キヤノン株式会社 静電荷像現像用トナー
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US5674488A (en) 1994-10-07 1997-10-07 Reich; John J. Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
JP2780154B2 (ja) 1995-02-17 1998-07-30 株式会社ヤクルト本社 ヨーグルト
JPH0840981A (ja) 1995-03-24 1996-02-13 Nissui Pharm Co Ltd エイコサペンタエノイルグリセライド
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JPH0959206A (ja) 1995-08-25 1997-03-04 Nippon Oil & Fats Co Ltd エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
GB9519661D0 (en) 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US6248398B1 (en) 1996-05-22 2001-06-19 Applied Materials, Inc. Coater having a controllable pressurized process chamber for semiconductor processing
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6331568B1 (en) 1996-10-11 2001-12-18 Scotia Holdings Plc. Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
JP4176166B2 (ja) 1996-11-15 2008-11-05 持田製薬株式会社 横紋筋融解症治療剤
EP0843972B1 (en) 1996-11-20 2002-07-31 N.V. Nutricia Nutritional composition comprising fats for the treatment of the metabolic syndrome
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
JPH1180083A (ja) 1997-09-10 1999-03-23 Nof Corp エイコサペンタエン酸エステルの製造方法
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1025842B1 (en) 1997-10-30 2004-07-21 Morishita Jintan Co., Ltd. Double-leyered capsule of unsaturated fatty acid or derivative thereof and process for producing the same
TR200001522T2 (tr) 1997-11-25 2000-12-21 Warner-Lambert Company Lipoprotein oksidasyonunun inhibisyonu.
EP1039893B1 (en) 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
US6077525A (en) 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
DE19830375A1 (de) 1998-07-08 2000-01-13 K D Pharma Bexbach Gmbh Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen
NZ500703A (en) 1998-11-04 2001-06-29 F Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CA2260397A1 (en) 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
HK1042240B (en) 1999-03-03 2004-05-07 Eurovita A/S Pharmaceuticals, dietary supplements and cosmetic compositions comprising a fatty acid and ginger
CA2362515C (en) 1999-03-04 2008-07-15 Suntory Limited Utilization of material containing docosapentaenoic acid
US20020054871A1 (en) 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
US7112609B2 (en) 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
CA2311974A1 (en) 1999-06-28 2000-12-28 Nisshin Flour Milling Co., Ltd. Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
DE59914760D1 (de) 1999-07-28 2008-06-26 Swiss Caps Rechte & Lizenzen Präparat zur Verwendung als Medikament und/oder Nahrungsmittelergänzung
JP2001039981A (ja) 1999-07-30 2001-02-13 Nissan Chem Ind Ltd アゾール縮合ピリミジン誘導体及び除草剤
CA2382262C (en) 1999-08-30 2004-12-07 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP4170542B2 (ja) 1999-11-18 2008-10-22 日油株式会社 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
EP1125914A1 (en) 2000-02-14 2001-08-22 Nisshin Flour Milling Co., Ltd. Process for separating and purifying eicosapentaenoic acid or its ester
KR20070104953A (ko) 2000-03-17 2007-10-29 아지노모토 가부시키가이샤 신경 장애용 약제
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
WO2002011723A1 (en) 2000-08-04 2002-02-14 Mason R Preston Synergistic effect of amlodipine and atorvastatin
JP4391673B2 (ja) 2000-08-08 2009-12-24 花王株式会社 油脂組成物
WO2002013797A2 (en) 2000-08-15 2002-02-21 Pfizer Products Inc. Therapeutic combination of a cetp inhibitor and atorvastatin
US20030195246A1 (en) 2000-08-16 2003-10-16 Takeshi Nakamura Seamless soft capsule preparations containing dihydrobenzofuran derivatives
US6383482B1 (en) 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
GB0101198D0 (en) 2001-01-17 2001-02-28 Scherer Technologies Inc R P Ingestible compositions containing an odoriferous oil
WO2002057795A2 (en) 2001-01-19 2002-07-25 Cambridge Scientific, Inc. Methods of diagnosis and treatment of osteoporosis
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
CZ299784B6 (cs) 2001-05-30 2008-11-26 Laxdale Limited Lécivo obsahující EPA a ubichinon pro lécení non-Hodgkinova lymfomu, psychiatrických a neurologických chorob
JP2003006690A (ja) 2001-06-20 2003-01-10 Ishikawajima Harima Heavy Ind Co Ltd 駐車装置の出庫情報表示装置
US20120214771A1 (en) 2001-07-27 2012-08-23 Fontini Sampalis Compositions for treatment of cardiometabolic disorders
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
WO2003043570A2 (en) 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040018248A1 (en) 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
JP2003306690A (ja) 2002-02-18 2003-10-31 Nooburu:Kk 多価不飽和脂肪酸含有油脂組成物
US20030166614A1 (en) 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
BR0309740A (pt) 2002-05-03 2005-02-22 Pronova Biocare As Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
WO2003103582A2 (en) 2002-06-05 2003-12-18 Ivax Corporation Reduction of gelatin cross-linking
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US20040001874A1 (en) 2002-06-24 2004-01-01 Vital Living, Inc. Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
MXPA04012740A (es) 2002-07-02 2005-03-23 Galileo Pharmaceuticals Inc Composiciones y metodos para reduccion de sintomas inflamatorios y/o biomarcadores en pacientes femeninos.
US20060211761A1 (en) 2002-07-08 2006-09-21 Yatendra Kumar Hmg-coa-reductase inhibitors
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
EP1547588B1 (en) 2002-08-20 2013-12-11 Kowa Company, Ltd. Soft capsule preparation
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
AU2003284617A1 (en) 2002-11-22 2004-06-18 Nippon Suisan Kaisha, Ltd. Composition containing organic substance having double bond with improved oxidation stability
ITMI20022511A1 (it) 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
EP1581496A4 (en) 2002-12-02 2008-04-23 Gilead Sciences Inc 2-SUBSTITUTED 3-PROPENAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2512666A1 (en) 2003-01-08 2004-07-29 Flacco-Nesselroad Family Trust Combination therapy for anticoagulation
GB0301701D0 (en) 2003-01-24 2003-02-26 Ensay Ltd Psoriasis and Eicosapentaenoic acid
CN1816287A (zh) 2003-01-31 2006-08-09 宝洁公司 改善哺乳动物角质组织外观的方法
EP1602372B1 (en) 2003-02-07 2016-08-31 Mochida Pharmaceutical Co., Ltd. Drug for improving prognosis for subarachnoid hemorrhage
CA2516333C (en) 2003-02-21 2011-08-23 Mochida Pharmaceutical Co., Ltd. Drug for reducing side effects in ribavirin / interferon combination therapy
WO2004078166A2 (en) 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
RU2356247C2 (ru) 2003-03-18 2009-05-27 Новартис Аг Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US6846942B2 (en) 2003-05-20 2005-01-25 David Rubin Method for preparing pure EPA and pure DHA
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
US20070098787A1 (en) 2003-06-20 2007-05-03 Mochida Pharmaceutical Co., Ltd. Composition for preventing and treating varicose veins of lower extremities
US20050042214A1 (en) 2003-07-15 2005-02-24 Gershwin M. Eric Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
PT1558220E (pt) 2003-07-24 2010-03-12 Rasendrakumar Jha Composições orais para tratamento da diabetes
IL158553A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Method for preparing phosphatidylserine containing omega-3 acid moieties
CA2542574C (en) 2003-11-12 2014-03-18 E. I. Du Pont De Nemours And Company Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7022713B2 (en) 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
EP1591114A1 (en) 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US20050244367A1 (en) 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
WO2005114190A2 (en) 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
TW200613009A (en) 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
WO2006017627A2 (en) 2004-08-06 2006-02-16 Barry Sears Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
NZ552389A (en) 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
US20090042979A1 (en) 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
WO2007130714A1 (en) 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
WO2007130713A1 (en) 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US9452150B2 (en) 2004-08-18 2016-09-27 Mochida Pharmaceutical Co., Ltd. Jelly composition
CA2578224A1 (en) 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
EP1782801A4 (en) 2004-08-27 2008-08-06 Senju Pharma Co EYEWASH FLUID FOR THERAPY DRY EYES
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
WO2006035418A2 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
US20100021555A1 (en) 2004-10-15 2010-01-28 Karl Geiringer Compositions containing high omega-3 and low saturated fatty acid levels
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
AU2005306320B2 (en) 2004-11-19 2011-09-08 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
FR2878747B1 (fr) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
CN101098690A (zh) 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US20090239927A1 (en) 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
US20060211762A1 (en) 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060135610A1 (en) 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20080200707A1 (en) 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
EP1834639B8 (en) 2005-01-04 2016-12-07 Mochida Pharmaceutical Co., Ltd. Remedial agent for fat toxicity
NZ560481A (en) 2005-01-10 2010-02-26 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions
US20060172012A1 (en) 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20060189682A1 (en) 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
JP2008530250A (ja) 2005-02-17 2008-08-07 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
US20100254951A1 (en) 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
CA2600429A1 (en) 2005-03-08 2006-09-14 Reliant Pharmaceuticals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
CN102526733B (zh) 2005-07-08 2014-09-03 持田制药株式会社 用于预防心血管事件发病的组合物
JP5134916B2 (ja) 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
EP1919468A4 (en) 2005-07-18 2010-02-10 Reliant Pharmaceuticals Inc TREATMENT WITH CHOLESTEROL ABSORPTION INHIBITORS BASED ON AZETIDINONE AND OMEGA-3 FATTY ACID AND COMBINATION PRODUCT THEREOF
RU2290185C1 (ru) 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
BRPI0614417A2 (pt) 2005-07-28 2011-03-29 Reliant Pharmaceuticals Inc composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
RU2302248C2 (ru) 2005-08-30 2007-07-10 Федеральное государственное унитарное предприятие Тихоокеанский научно-исследовательский рыбохозяйственный центр Средство, обладающее липидкорригирующими, гипокоагуляционными и антиоксидантными свойствами
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20090227602A1 (en) 2005-10-28 2009-09-10 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070105793A1 (en) 2005-11-04 2007-05-10 Curt Hendrix Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
JP5113527B2 (ja) 2005-11-11 2013-01-09 持田製薬株式会社 ゼリー組成物
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
CA2628666A1 (en) 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
US7652068B2 (en) 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
WO2007081773A2 (en) 2006-01-05 2007-07-19 Reliant Pharmaceuticals, Inc Treatment of fatty liver
EP1905424A3 (en) 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
JP4005104B2 (ja) * 2006-02-07 2007-11-07 持田製薬株式会社 脳卒中再発予防用組成物
KR101336756B1 (ko) 2006-02-07 2013-12-04 모치다 세이야쿠 가부시키가이샤 뇌졸중 재발 예방용 조성물
JP5069448B2 (ja) 2006-02-07 2012-11-07 持田製薬株式会社 脳卒中再発予防用組成物
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
CN101437508A (zh) 2006-03-03 2009-05-20 孟山都技术有限公司 用于改善心血管健康的十八碳四烯酸
EP2081550B2 (en) 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
US8853256B2 (en) 2006-05-31 2014-10-07 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of cardiovascular event in multiple risk patient
US20070292501A1 (en) 2006-06-05 2007-12-20 Udell Ronald G Chewable soft gelatin capsules
EP2124923A1 (en) 2006-06-07 2009-12-02 Imagination Unlimited B.V. Use of a polyphenol in the treatment of the metabolic syndrome and endothelial dysfunction or other vascular sequellae.
AU2007270135B9 (en) 2006-07-05 2013-06-27 Fermentalg Production of ultrapure EPA and polar lipids from largely heterotrophic culture
EP2068861A4 (en) 2006-07-21 2010-01-06 Reliant Pharmaceuticals Inc COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND USE THEREOF IN THE TREATMENT OF PERIPHERAL ARTERIES DISEASE AND INTERMITTENT CLAUDICATION
WO2008012329A2 (en) 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
KR101411758B1 (ko) 2006-09-05 2014-06-25 큐피가부시키가이샤 프로스태글란딘 지방 에멀젼, 이의 제조 방법, 그 에멀젼의안정화 방법 및 에멀젼화제
CN101553221A (zh) 2006-10-10 2009-10-07 瑞莱恩特医药品有限公司 用于降低APO-B水平的抑制素和ω-3脂肪酸
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
KR20090086078A (ko) 2006-10-13 2009-08-10 릴라이언트 파마슈티컬스 인코퍼레이티드 항부정맥제 및 오메가-3 지방산 및 이들의 조합 생성물로의 치료
JP2010506920A (ja) 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
WO2008047340A1 (en) 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
US20080125490A1 (en) 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
WO2008088030A1 (ja) 2007-01-17 2008-07-24 Mochida Pharmaceutical Co., Ltd. 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
US8008328B2 (en) 2007-01-23 2011-08-30 Reddy Us Therapeutics, Inc. Methods for the treatment of diabetes-associated dyslipdemia
US20080185198A1 (en) 2007-02-02 2008-08-07 Steven Mark Jones Next generation hybrid III parallel/series hybrid system
AU2008215077B2 (en) 2007-02-15 2012-08-23 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US20100055175A1 (en) 2007-03-06 2010-03-04 James Nugent Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
WO2008115529A1 (en) 2007-03-20 2008-09-25 Reliant Pharmaceuticals, Inc. Compositions comprising omega-3 fatty acids and cetp inhibitors
WO2008145170A1 (de) 2007-05-31 2008-12-04 Siemens Aktiengesellschaft Verfahren zum konfigurieren einer automatisierungsanlage
US20080299187A1 (en) 2007-06-01 2008-12-04 Joar Opheim Substances for Reducing Occurence of Major Cardiac Events in Humans
US20100119598A1 (en) 2007-06-29 2010-05-13 Takeda Pharmaceutical Company Limited Seamless capsule
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
US8361534B2 (en) 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
US8377496B2 (en) 2007-12-20 2013-02-19 Abbott Laboratories Stable nutritional powder
WO2009087938A1 (ja) 2008-01-10 2009-07-16 Takeda Pharmaceutical Company Limited カプセル製剤
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
WO2009139641A1 (en) 2008-05-15 2009-11-19 Pronova Biopharma Norge As Krill oil process
JPWO2009142242A1 (ja) 2008-05-20 2011-09-29 持田製薬株式会社 ハイリスク患者の心血管イベント予防用組成物
US20110082119A1 (en) 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
JPWO2009151125A1 (ja) 2008-06-13 2011-11-17 持田製薬株式会社 肝障害の診断及び治療
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EP2308493A4 (en) 2008-07-07 2013-05-01 Mochida Pharm Co Ltd ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
ES2632967T3 (es) 2008-09-02 2017-09-18 Amarin Pharmaceuticals Ireland Limited Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
US9006285B2 (en) 2008-09-30 2015-04-14 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for hepatitis C
US20100130608A1 (en) 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
WO2010083615A1 (en) 2009-01-26 2010-07-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
SI2596786T1 (sl) 2009-02-10 2020-03-31 Amarin Pharmaceuticals Ireland Limited, Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
ES2979118T3 (es) 2009-03-09 2024-09-24 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un ácido graso libre, y procedimientos y usos de las mismas
US8241672B2 (en) 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20120046251A1 (en) 2009-04-06 2012-02-23 The Regents Of The University Of California Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
LT2424356T (lt) 2009-04-29 2017-11-27 Amarin Pharmaceuticals Ireland Limited Stabili farmacinė kompozicija ir jos panaudojimo būdai
CA2762939C (en) 2009-05-22 2017-07-18 Mochida Phamaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
RU2402326C1 (ru) 2009-06-22 2010-10-27 Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) Способ коррекции инсулинорезистентности при метаболическом синдроме
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
SG178948A1 (en) 2009-09-01 2012-04-27 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
EP2490026A4 (en) 2009-10-16 2013-08-21 Mochida Pharm Co Ltd MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
SG182414A1 (en) 2010-01-08 2012-08-30 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
US20110178105A1 (en) 2010-01-15 2011-07-21 E.I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
US20110218243A1 (en) 2010-03-04 2011-09-08 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
US8846321B2 (en) 2010-03-12 2014-09-30 President And Fellows Of Harvard College Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
AU2011249630B2 (en) 2010-05-05 2014-01-23 St. Giles Foods Limited Edible compositions and methods of manufacturing edible compositions
EP2664328B2 (en) 2010-06-30 2022-04-27 Mochida Pharmaceutical Co., Ltd. Omega3 fatty acid compound preparation
AR082930A1 (es) 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
US10557856B2 (en) 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
EP2630501A4 (en) 2010-10-20 2014-04-16 Glycomark Inc ENHANCED IDENTIFICATION OF A PREDABWEE STATE USING AS MARKERS AVERAGE GLYCEMIA AND 1,5-ANHYDROGLUCITOL IN COMBINATION
CN103338762B (zh) 2010-11-09 2015-03-25 持田制药株式会社 血糖值上升抑制剂
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2471537A1 (en) 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2502506A1 (en) 2011-03-21 2012-09-26 Abbott Laboratories Methods for improving bone health in infants using long chain polyunsaturated fatty acids
KR101310710B1 (ko) 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8660662B2 (en) 2011-04-22 2014-02-25 Medtronic, Inc. Low impedance, low modulus wire configurations for a medical device
UA115309C2 (uk) 2011-04-27 2017-10-25 Іоніс Фармасьютікалз, Інк. Модуляція експресії аполіпопротеїну ciii (apociii)
US20130095179A1 (en) 2011-09-15 2013-04-18 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
JPWO2013089157A1 (ja) 2011-12-12 2015-04-27 独立行政法人国立循環器病研究センター オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する高脂血症治療剤
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
WO2013136277A1 (en) 2012-03-13 2013-09-19 Unimark Remedies Ltd. Pharmaceutical compositions for treatment of cardiovascular diseases
EP3072510B1 (en) 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
CA2873580C (en) 2012-05-15 2021-02-02 Kyushu University, National University Corporation Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity c-reactive protein
BR112014029757A2 (pt) 2012-05-30 2017-06-27 Clariant Finance Bvi Ltd composição contendo tensoativos do tipo aminoácido, betaínas e n-metil-n-acilglucaminas e tendo qualidade de espuma melhorada e maior viscosidade
US20140080850A1 (en) 2012-06-05 2014-03-20 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
US20130324607A1 (en) 2012-06-05 2013-12-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypercholesterolemia
JP2015520194A (ja) 2012-06-07 2015-07-16 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物標的指向化のためのナノ療法
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20150157593A1 (en) 2012-06-29 2015-06-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
EP2866800A4 (en) 2012-06-29 2015-12-16 Amarin Pharmaceuticals Ie Ltd METHOD FOR THE TREATMENT OF METABOLIC SYNDROME IN CHILDREN
US20140004183A1 (en) 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
US20140005265A1 (en) 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
JP5583179B2 (ja) 2012-08-03 2014-09-03 株式会社カイジョー ボンディング装置
WO2014050692A1 (ja) 2012-09-28 2014-04-03 持田製薬株式会社 糖尿病新規発症低減用組成物
EP2719382A1 (en) 2012-10-12 2014-04-16 Mochida Pharmaceutical Co., Ltd. Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US20140142127A1 (en) 2012-10-23 2014-05-22 Almburg, Llc Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils
SG11201503440UA (en) 2012-11-02 2015-06-29 Heart Care Western Australia Pty Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US8840742B2 (en) 2012-11-07 2014-09-23 The Boeing Company System and method of detecting a missing tow in a composite layup
US8703188B1 (en) 2012-11-19 2014-04-22 Azanta A/S Dispersible tablet
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140213648A1 (en) 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140221452A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US20140221358A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140221676A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140242216A1 (en) 2013-02-24 2014-08-28 Mead Johnson Nutrition Company Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
US20140249225A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20140249214A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Co-administration of warfarin and ethyl eicosapentaenoate
WO2014134466A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited. Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US20140249220A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
US9661874B2 (en) 2013-03-11 2017-05-30 Mead Johnson Nutrition Company Nutritional compositions containing structured fat globules and uses thereof
US20140255537A1 (en) 2013-03-11 2014-09-11 Mead Johnson Nutrition Company Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
US20140275252A1 (en) 2013-03-14 2014-09-18 Amarin Pharmaceuticals Ireland Limited Methods of treating traumatic brain injury
US20140271907A1 (en) 2013-03-14 2014-09-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9889108B2 (en) 2013-03-15 2018-02-13 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
CN105210291B (zh) 2013-03-15 2018-10-02 维斯普瑞公司 可调滤波器系统、装置以及方法
WO2014179325A1 (en) 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Omega-3 fatty acid formulations for use as pharmaceutical treatment
KR102240429B1 (ko) 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
US20140357717A1 (en) 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
CA2913634C (en) 2013-06-07 2022-08-09 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
US20160135702A1 (en) 2013-06-21 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Techniques for Predicting Cardiac Arrhythmias Based on Signals from Leads of Electrocardiography
EP3023098B1 (en) 2013-07-18 2020-06-24 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of omega-3 fatty acid
CN111888343A (zh) 2013-07-18 2020-11-06 持田制药株式会社 ω-3脂肪酸的自乳化组合物
US20150045431A1 (en) 2013-08-06 2015-02-12 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
US20150051282A1 (en) 2013-08-14 2015-02-19 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US20150073050A1 (en) 2013-09-09 2015-03-12 Amarin Pharmaceuticals Ireland Limited Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
EP3054940B1 (en) 2013-10-07 2020-09-23 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
PL3129018T3 (pl) 2014-04-11 2020-05-18 Cymabay Therapeutics, Inc. Leczenie NAFLD i NASH
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
CA2974495C (en) 2015-01-21 2023-05-23 Mochida Pharmaceutical Co., Ltd. .omega.-3 fatty acid self-emulsifying composition
CA2974321C (en) 2015-01-21 2023-09-05 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.-3 fatty acid
EA039310B1 (ru) 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска
US20180028480A1 (en) 2015-03-02 2018-02-01 Richard Preston Mason Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20170151202A1 (en) 2015-09-09 2017-06-01 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2017077528A2 (en) 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
RS61403B1 (sr) 2016-07-29 2021-02-26 Kowa Co Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US20190054054A1 (en) 2017-08-15 2019-02-21 Amarin Pharmaceuticals Ireland Limited Methods reducing or preventing oxidation of high density lipoprotein (HDL)
US20190054058A1 (en) 2017-08-15 2019-02-21 Amarin Pharmaceuticals Ireland Limited Methods of Treating or Preventing Bone Loss
US20190209506A1 (en) 2018-01-09 2019-07-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190275057A1 (en) 2018-03-06 2019-09-12 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
MX2021001906A (es) 2018-08-17 2021-04-28 Amarin Pharmaceuticals Ie Ltd Metodos para reducir la necesidad de revascularizacion arterial periferica en un sujeto tratado con estatinas.
KR20230038594A (ko) 2018-09-24 2023-03-20 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
KR20210066831A (ko) 2018-09-26 2021-06-07 애머린 파마슈티칼스 아일랜드 리미티드 공기 오염에 대한 노출에 의해 생긴 질환 및/또는 장애의 치료 또는 예방을 위한 조성물 및 방법
CN113423395A (zh) 2019-02-15 2021-09-21 阿马里纳药物爱尔兰有限公司 通过增加血清及血浆epa及dpa水平来降低经他汀治疗的受试者的心血管事件的风险的方法
JP2021015274A (ja) 2019-07-12 2021-02-12 キヤノン株式会社 エレクトロクロミック素子及び光学装置、調光窓、撮像装置
CN114144192A (zh) 2019-08-01 2022-03-04 赢创运营有限公司 包含ω-3脂肪酸盐和来自乳香属物种的胶树脂提取物的制剂
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582698A (zh) * 2012-06-29 2015-04-29 阿玛林制药爱尔兰有限公司 在接受抑制素治疗的受试者中降低心血管事件风险的方法

Also Published As

Publication number Publication date
JP2024109575A (ja) 2024-08-14
FI4056176T3 (fi) 2024-05-30
US20210154164A1 (en) 2021-05-27
HRP20240898T1 (hr) 2024-10-11
IL279494A (en) 2021-01-31
KR20200094199A (ko) 2020-08-06
US20200093778A1 (en) 2020-03-26
EP4056176A1 (en) 2022-09-14
DK4056176T3 (da) 2024-05-06
US20220000829A1 (en) 2022-01-06
MA51765A (fr) 2020-12-16
SI4056176T1 (sl) 2024-09-30
US11369582B2 (en) 2022-06-28
ES2983568T3 (es) 2024-10-23
PT4056176T (pt) 2024-05-27
US11000499B2 (en) 2021-05-11
US11116743B2 (en) 2021-09-14
US10786478B2 (en) 2020-09-29
AU2023200785A1 (en) 2023-03-09
KR20230038594A (ko) 2023-03-20
EP3700518A4 (en) 2020-12-16
US20200338035A1 (en) 2020-10-29
ZA202110659B (en) 2023-08-30
AU2023200783B2 (en) 2023-04-13
AU2023226708B2 (en) 2025-08-28
US20200138768A1 (en) 2020-05-07
JP2021510730A (ja) 2021-04-30
AU2023226708A1 (en) 2023-09-21
AU2023200781B2 (en) 2023-04-06
ZA202007993B (en) 2022-04-28
MX2023011456A (es) 2023-10-18
AU2023200781A1 (en) 2023-03-09
WO2020068163A1 (en) 2020-04-02
RS65750B1 (sr) 2024-08-30
CL2021000645A1 (es) 2021-07-30
US11116742B2 (en) 2021-09-14
HUE067138T2 (hu) 2024-10-28
EP4056176B1 (en) 2024-04-24
US20200093777A1 (en) 2020-03-26
AU2019349563A1 (en) 2021-02-11
JP7481071B2 (ja) 2024-05-10
KR20210110890A (ko) 2021-09-09
AU2023200783A1 (en) 2023-03-09
SMT202400320T1 (it) 2024-09-16
AU2023200785B2 (en) 2023-04-20
EP3750536A1 (en) 2020-12-16
MA51766A (fr) 2020-12-16
US11717504B2 (en) 2023-08-08
AU2023200784B2 (en) 2023-04-13
US20210137873A1 (en) 2021-05-13
CL2023000767A1 (es) 2023-09-29
MX2021002553A (es) 2021-04-29
PL4056176T3 (pl) 2024-08-26
US20230105054A1 (en) 2023-04-06
US12246003B2 (en) 2025-03-11
LT4056176T (lt) 2024-08-12
AU2019349563B2 (en) 2023-06-08
MA50490A (fr) 2020-09-02
TN2021000013A1 (en) 2022-10-03
SG11202102872QA (en) 2021-04-29
JP2022062151A (ja) 2022-04-19
CL2022000997A1 (es) 2022-11-18
US11298333B1 (en) 2022-04-12
EP3700518A1 (en) 2020-09-02
EP3750535A1 (en) 2020-12-16
AU2023200784A1 (en) 2023-03-09
KR20240135078A (ko) 2024-09-10
JP7020756B2 (ja) 2022-02-16
NI202100014A (es) 2021-06-22
US10668042B2 (en) 2020-06-02
CN112218630A (zh) 2021-01-12
US20210100768A1 (en) 2021-04-08
BR112021005580A2 (pt) 2021-06-29
KR102296068B1 (ko) 2021-09-02

Similar Documents

Publication Publication Date Title
JP7481071B2 (ja) 対象の心血管イベントのリスクを低減する方法
CN112912071A (zh) 降低接受他汀类药物治疗的受试者对外周动脉血运重建的需求的方法
CN114980973A (zh) 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
CN113423395A (zh) 通过增加血清及血浆epa及dpa水平来降低经他汀治疗的受试者的心血管事件的风险的方法
CN115697339A (zh) 治疗和/或预防有需要的受试者的病毒感染和/或由病毒引起的疾病的方法
WO2022212655A1 (en) Compositions comprising epa and colchicine and methods of using the same for reducing the risk of cardiovascular events in a subject
HK40058705A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40037491A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40044137A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40079256A (en) Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
CN113332269A (zh) 降低受试者的心血管事件的风险的方法
CA3160827C (en) Methods of reducing the risk of cardiovascular events in a subject
HK40053699A (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
HK40060705A (en) Methods of reducing the risk of a cardiovascular event in a statin-treated subject by increasing serum and plasma epa and dpa levels
KR20240012390A (ko) 심부전의 위험을 감소시키는 방법
HK40079514B (en) Methods of reducing the risk of cardiovascular events in a subject
HK40079514A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40038227A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40038229A (en) Methods of reducing the risk of cardiovascular events in a subject

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037491

Country of ref document: HK